Metabolic dysfunction affects 70% of the population who are overweight, obese, or pre-diabetic, with over 60% living with chronic illness. Additionally, 40% of approved drugs and 90% of pipeline APIs remain insoluble, leading to reduced efficacy and higher costs.
